{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:19:06Z","timestamp":1787509146486,"version":"build-2736575974"},"reference-count":63,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Children with Down syndrome have a markedly increased risk of developing myeloid leukemia. Although having an excellent prognosis, 10% to 20% develop relapsed or refractory disease with poor survival, highlighting the need for new targeted approaches. The pathogenesis of myeloid leukemia of Down syndrome (ML-DS) is tightly linked to fetal hematopoiesis and mutations in GATA1, generating the truncated GATA1 short (GATA1s) isoform. We identified Delta-like noncanonical Notch ligand 1 (DLK1) as a direct GATA1s target. DLK1, a paternally imprinted transmembrane protein, is highly expressed in fetal liver CD34+ cells but absent in adult hematopoiesis, making it an attractive immunotherapeutic target. Chromatin profiling revealed GATA1s occupancy at a distal enhancer within the DLK1-DIO3 locus, driving aberrant DLK1 upregulation in ML-DS. Functional studies demonstrated that DLK1 is a leukemia dependency, as its genetic ablation impaired proliferation and engraftment, induced apoptosis, and altered Notch and \u03b2-catenin signaling. Therapeutically, a DLK1-directed antibody-drug conjugate\u2013induced selective cytotoxicity, abrogated colony formation, and significantly prolonged survival in refractory ML-DS patient-derived xenograft (PDX) models, achieving durable remissions at higher doses. These findings establish DLK1 as a leukemia-specific vulnerability and provide preclinical proof-of-concept for DLK1-targeted therapies in ML-DS and other leukemias with fetal-like expression programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018830","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T18:54:38Z","timestamp":1775588078000},"page":"4120-4133","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["DLK1 is a GATA1s-driven dependency and therapeutic target in Down syndrome\u2013associated myeloid leukemia"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3926-2417","authenticated-orcid":false,"given":"Lonneke J.","family":"Verboon","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4162-3004","authenticated-orcid":false,"given":"Sonali P.","family":"Barwe","sequence":"additional","affiliation":[{"name":"2Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Tavenner","sequence":"additional","affiliation":[{"name":"2Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6114-9206","authenticated-orcid":false,"given":"Joshua R.","family":"Faust","sequence":"additional","affiliation":[{"name":"2Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Issa","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9230-6004","authenticated-orcid":false,"given":"Jos\u00e9","family":"Gon\u00e7alves-Dias","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5417-8950","authenticated-orcid":false,"given":"Konstantin","family":"Schuschel","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0865-9582","authenticated-orcid":false,"given":"Raj","family":"Bhayadia","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"van Berkel","sequence":"additional","affiliation":[{"name":"3ADC Therapeutics (UK) Ltd, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-7040","authenticated-orcid":false,"given":"Aimy","family":"Sebastian","sequence":"additional","affiliation":[{"name":"4Physical and Life Sciences Directorate, Lawrence Livermore National Laboratory, Livermore, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3702-7923","authenticated-orcid":false,"given":"Rhonda E.","family":"Ries","sequence":"additional","affiliation":[{"name":"5Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-2775","authenticated-orcid":false,"given":"Sophie","family":"Paczesny","sequence":"additional","affiliation":[{"name":"6Hollings Cancer Center and Departments of Microbiology and Immunology and Pediatrics, Medical University of South Carolina, Charleston, SC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6276-4423","authenticated-orcid":false,"given":"Soheil","family":"Meshinchi","sequence":"additional","affiliation":[{"name":"5Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-186X","authenticated-orcid":false,"given":"Johann","family":"Hitzler","sequence":"additional","affiliation":[{"name":"7The Hospital for Sick Children, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5336-0216","authenticated-orcid":false,"given":"Yana","family":"Pikman","sequence":"additional","affiliation":[{"name":"8Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"},{"name":"9Division of Hematology\/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2854-9014","authenticated-orcid":false,"given":"E. Anders","family":"Kolb","sequence":"additional","affiliation":[{"name":"2Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4047-975X","authenticated-orcid":false,"given":"Dirk","family":"Heckl","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"},{"name":"10Institute for Experimental Hematology and Oncology, Goethe University Frankfurt, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-0727","authenticated-orcid":false,"given":"Jan-Henning","family":"Klusmann","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0465-578X","authenticated-orcid":false,"given":"Anilkumar","family":"Gopalakrishnapillai","sequence":"additional","affiliation":[{"name":"2Lisa Dean Moseley Foundation Institute for Cancer and Blood Disorders, Nemours Children\u2019s Hospital, Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"9199","key":"2026062308475876300_bib1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0140-6736(99)05264-2","article-title":"Risks of leukaemia and solid tumours in individuals with Down's syndrome","volume":"355","author":"Hasle","year":"2000","journal-title":"Lancet (London, England)"},{"issue":"11","key":"2026062308475876300_bib2","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/gim.2016.23","article-title":"Low risk of solid tumors in persons with Down syndrome","volume":"18","author":"Hasle","year":"2016","journal-title":"Genet Med"},{"key":"2026062308475876300_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2021.03.001","article-title":"Leukemia risk in a cohort of 3.9 million children with and without Down syndrome","volume":"234","author":"Marlow","year":"2021","journal-title":"J Pediatr"},{"issue":"11","key":"2026062308475876300_bib4","first-page":"1677","article-title":"Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group","volume":"10","author":"Creutzig","year":"1996","journal-title":"Leukemia"},{"issue":"5","key":"2026062308475876300_bib5","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2353\/jmoldx.2009.080132","article-title":"Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology","volume":"11","author":"Xavier","year":"2009","journal-title":"The J Mol Diagn"},{"issue":"6","key":"2026062308475876300_bib6","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1046\/j.1365-2141.2003.04229.x","article-title":"Transient leukaemia \u2013 a benign form of leukaemia in newborn infants with trisomy 21","volume":"120","author":"Zipursky","year":"2003","journal-title":"Br J Haematol"},{"key":"2026062308475876300_bib7","doi-asserted-by":"crossref","first-page":"101154","DOI":"10.1016\/j.blre.2023.101154","article-title":"Down syndrome and leukemia: an insight into the disease biology and current treatment options","volume":"64","author":"Barwe","year":"2024","journal-title":"Blood Rev"},{"issue":"23","key":"2026062308475876300_bib8","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1182\/blood.2021012206","article-title":"High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial","volume":"138","author":"Hitzler","year":"2021","journal-title":"Blood"},{"issue":"25","key":"2026062308475876300_bib9","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/blood-2017-01-765057","article-title":"Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial","volume":"129","author":"Uffmann","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2026062308475876300_bib10","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1182\/bloodadvances.2022009381","article-title":"Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome","volume":"7","author":"Raghuram","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2026062308475876300_bib11","doi-asserted-by":"crossref","first-page":"e31141","DOI":"10.1002\/pbc.31141","article-title":"Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome","volume":"71","author":"Miladinovic","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"2026062308475876300_bib12","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng955","article-title":"Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome","volume":"32","author":"Wechsler","year":"2002","journal-title":"Nat Genet"},{"issue":"8","key":"2026062308475876300_bib13","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.3324\/haematol.2018.191338","article-title":"GATA1s exerts developmental stage-specific effects in human hematopoiesis","volume":"103","author":"Gialesaki","year":"2018","journal-title":"Haematologica"},{"issue":"10","key":"2026062308475876300_bib14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood.2022017619","article-title":"RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia","volume":"141","author":"Gialesaki","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026062308475876300_bib15","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1038\/s41467-025-59930-9","article-title":"Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12","volume":"16","author":"Troester","year":"2025","journal-title":"Nat Commun"},{"issue":"16","key":"2026062308475876300_bib16","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1101\/gad.14.16.1997","article-title":"The Dlk1 and Gtl2 genes are linked and reciprocally imprinted","volume":"14","author":"Schmidt","year":"2000","journal-title":"Genes Dev"},{"issue":"1","key":"2026062308475876300_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1432-0436.2000.066001049.x","article-title":"Does Fetal antigen 1 (FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? A study of FA1 in embryonic, fetal, and placental tissue and in maternal circulation","volume":"66","author":"Floridon","year":"2000","journal-title":"Differentiation"},{"issue":"8","key":"2026062308475876300_bib18","doi-asserted-by":"crossref","first-page":"e6709","DOI":"10.1371\/journal.pone.0006709","article-title":"Expression of stem cell markers in the human fetal kidney","volume":"4","author":"Metsuyanim","year":"2009","journal-title":"PLoS One"},{"issue":"4","key":"2026062308475876300_bib19","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00185891","article-title":"Fetal antigen 1 (FA1) in the human pancreas: cell type expression, topological and quantitative variations during development","volume":"187","author":"Tornehave","year":"1993","journal-title":"Anat Embryol"},{"issue":"1","key":"2026062308475876300_bib20","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41467-025-57096-y","article-title":"Continuous map of early hematopoietic stem cell differentiation across human lifetime","volume":"16","author":"Komic","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"2026062308475876300_bib21","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3390\/antib4020071","article-title":"A monoclonal antibody to human DLK1 reveals differential expression in cancer and absence in healthy tissues","volume":"4","author":"Bujak","year":"2015","journal-title":"Antibodies"},{"issue":"8","key":"2026062308475876300_bib22","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/sj.leu.2403832","article-title":"Dlk1 in normal and abnormal hematopoiesis","volume":"19","author":"Sakajiri","year":"2005","journal-title":"Leukemia"},{"issue":"1","key":"2026062308475876300_bib23","first-page":"61","article-title":"Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells","volume":"22","author":"Qi","year":"2008","journal-title":"Int J Mol Med"},{"issue":"1","key":"2026062308475876300_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jb\/mvq034","article-title":"Dlk-1, a cell surface antigen on foetal hepatic stem\/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency","volume":"148","author":"Yanai","year":"2010","journal-title":"J Biochem"},{"issue":"1","key":"2026062308475876300_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1369\/00221554211048951","article-title":"Emerging roles of DLK1 in the stem cell niche and cancer stemness","volume":"70","author":"Grassi","year":"2022","journal-title":"J Histochem Cytochem"},{"issue":"12","key":"2026062308475876300_bib26","doi-asserted-by":"crossref","first-page":"R271","DOI":"10.1530\/ERC-21-0208","article-title":"The role of delta-like non-canonical Notch ligand 1 (DLK1) in cancer","volume":"28","author":"Pittaway","year":"2021","journal-title":"Endocrine-Related Cancer"},{"issue":"11","key":"2026062308475876300_bib27","article-title":"A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma","volume":"42","author":"Weiner","year":"2024","journal-title":"Cancer Cell"},{"issue":"suppl 13","key":"2026062308475876300_bib28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1158\/1538-7445.AM2018-744","article-title":"ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors [abstract]","volume":"78","author":"Zammarchi","year":"2018","journal-title":"Cancer Res"},{"issue":"11","key":"2026062308475876300_bib29","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/liv.15411","article-title":"DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma","volume":"42","author":"Zhai","year":"2022","journal-title":"Liver Int"},{"key":"2026062308475876300_bib30","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.lungcan.2021.01.014","article-title":"Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using (125)I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)","volume":"153","author":"Takagi","year":"2021","journal-title":"Lung Cancer"},{"issue":"6","key":"2026062308475876300_bib31","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.bbadis.2012.02.003","article-title":"Possible roles of DLK1 in the Notch pathway during development and disease","volume":"1822","author":"Falix","year":"2012","journal-title":"Biochim Biophys Acta"},{"issue":"20","key":"2026062308475876300_bib32","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1038\/s41388-020-1273-9","article-title":"Hypoxia-induced release, nuclear translocation, and signaling activity of a DLK1 intracellular fragment in glioma","volume":"39","author":"Grassi","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"2026062308475876300_bib33","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3892\/ol.2013.1346","article-title":"Effect of DLK1 on tumorigenesis in CD34(+)CD38(-) bone marrow cells in myelodysplastic syndromes","volume":"6","author":"Zhang","year":"2013","journal-title":"Oncol Lett"},{"issue":"10","key":"2026062308475876300_bib34","doi-asserted-by":"crossref","first-page":"107844","DOI":"10.1016\/j.isci.2023.107844","article-title":"Myeloid leukemia vulnerabilities embedded in long noncoding RNA locus MYNRL15","volume":"26","author":"Ng","year":"2023","journal-title":"iScience"},{"issue":"4","key":"2026062308475876300_bib35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/cells11040628","article-title":"Modeling Down syndrome myeloid leukemia by sequential introduction of GATA1 and STAG2 mutations in induced pluripotent stem cells with trisomy 21","volume":"11","author":"Barwe","year":"2022","journal-title":"Cells"},{"issue":"2","key":"2026062308475876300_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2019.06.007","article-title":"Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome","volume":"36","author":"Labuhn","year":"2019","journal-title":"Cancer Cell"},{"issue":"6","key":"2026062308475876300_bib37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/leu.2013.373","article-title":"GATA1s induces hyperproliferation of eosinophil precursors in Down syndrome transient leukemia","volume":"28","author":"Maroz","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"2026062308475876300_bib38","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1182\/blood.2021012231","article-title":"The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis","volume":"139","author":"Alejo-Valle","year":"2022","journal-title":"Blood"},{"key":"2026062308475876300_bib39","doi-asserted-by":"crossref","first-page":"e21856","DOI":"10.7554\/eLife.21856","article-title":"An efficient targeted nuclease strategy for high-resolution mapping of DNA binding sites","volume":"6","author":"Skene","year":"2017","journal-title":"eLife"},{"issue":"18","key":"2026062308475876300_bib40","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/bloodadvances.2020001592","article-title":"CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia","volume":"4","author":"Quagliano","year":"2020","journal-title":"Blood Adv"},{"key":"2026062308475876300_bib41","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fonc.2016.00162","article-title":"Generation of pediatric leukemia xenograft models in NSG-B2m mice: comparison with NOD\/SCID mice","volume":"6","author":"Gopalakrishnapillai","year":"2016","journal-title":"Front Oncol"},{"key":"2026062308475876300_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.leukres.2017.05.004","article-title":"Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia","volume":"58","author":"Gopalakrishnapillai","year":"2017","journal-title":"Leuk Res"},{"key":"2026062308475876300_bib43","unstructured":"Klusmann\n              JH\n            , BhayadiaR. lncScape. Accessed 14 April 2026. https:\/\/ag-klusmann.shinyapps.io\/lncScape\/."},{"issue":"6220","key":"2026062308475876300_bib44","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Tissue-based map of the human proteome","volume":"347","author":"Uhl\u00e9n","year":"2015","journal-title":"Science"},{"issue":"1","key":"2026062308475876300_bib45","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41467-017-00212-4","article-title":"The non-coding RNA landscape of human hematopoiesis and leukemia","volume":"8","author":"Schwarzer","year":"2017","journal-title":"Nat Commun"},{"issue":"suppl","key":"2026062308475876300_bib46","article-title":"PB1813: regulatory mechanisms and therapeutic potential of the Dlk1-DIO3 locus in pediatric acute megakaryoblastic leukemia [abstract]","volume":"7","author":"Verboon","year":"2023","journal-title":"Hemasphere"},{"issue":"1","key":"2026062308475876300_bib47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13148-019-0643-z","article-title":"Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival","volume":"11","author":"Sellers","year":"2019","journal-title":"Clin Epigenetics"},{"issue":"44","key":"2026062308475876300_bib48","doi-asserted-by":"crossref","first-page":"71466","DOI":"10.18632\/oncotarget.12214","article-title":"Targeting endogenous DLK1 exerts antitumor effect on hepatocellular carcinoma through initiating cell differentiation","volume":"7","author":"Cai","year":"2016","journal-title":"Oncotarget"},{"issue":"2","key":"2026062308475876300_bib49","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2012.070789","article-title":"Dlk1 is a negative regulator of emerging hematopoietic stem and progenitor cells","volume":"98","author":"Mirshekar-Syahkal","year":"2013","journal-title":"Haematologica"},{"issue":"2","key":"2026062308475876300_bib50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.stem.2015.11.001","article-title":"The Dlk1-Gtl2 locus preserves LT-HSC function by inhibiting the PI3K-mTOR pathway to restrict mitochondrial metabolism","volume":"18","author":"Qian","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2026062308475876300_bib51","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41598-019-38605-8","article-title":"The long non-coding RNA Meg3 is dispensable for hematopoietic stem cells","volume":"9","author":"Sommerkamp","year":"2019","journal-title":"Sci Rep"},{"issue":"2","key":"2026062308475876300_bib52","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.yexcr.2004.10.001","article-title":"dlk acts as a negative regulator of Notch1 activation through interactions with specific EGF-like repeats","volume":"303","author":"Baladr\u00f3n","year":"2005","journal-title":"Exp Cell Res"},{"issue":"17","key":"2026062308475876300_bib53","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1038\/s41388-018-0658-5","article-title":"Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling","volume":"38","author":"Huang","year":"2019","journal-title":"Oncogene"},{"issue":"1","key":"2026062308475876300_bib54","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-022-00369-9","article-title":"Dlk1 maintains adult mice long-term HSCs by activating Notch signaling to restrict mitochondrial metabolism","volume":"12","author":"Huang","year":"2023","journal-title":"Exp Hematol Oncol"},{"issue":"6","key":"2026062308475876300_bib55","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.bbamcr.2011.03.004","article-title":"The EGF-like proteins DLK1 and DLK2 function as inhibitory non-canonical ligands of NOTCH1 receptor that modulate each other's activities","volume":"1813","author":"S\u00e1nchez-Solana","year":"2011","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2026062308475876300_bib56","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.ymthe.2024.01.036","article-title":"DLK1\/DIO3 locus upregulation by a \u03b2-catenin-dependent enhancer drives cell proliferation and liver tumorigenesis","volume":"32","author":"Sanceau","year":"2024","journal-title":"Mol Ther"},{"issue":"11","key":"2026062308475876300_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2024.10.003","article-title":"A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma","volume":"42","author":"Hamilton","year":"2024","journal-title":"Cancer Cell"},{"issue":"1","key":"2026062308475876300_bib58","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/s41467-025-60649-w","article-title":"Identification of the Notch ligand DLK1 as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma","volume":"16","author":"Sun","year":"2025","journal-title":"Nat Commun"},{"issue":"4","key":"2026062308475876300_bib59","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3390\/cancers13040777","article-title":"Infant acute myeloid leukemia: a unique clinical and biological entity","volume":"13","author":"Calvo","year":"2021","journal-title":"Cancers"},{"key":"2026062308475876300_bib60","doi-asserted-by":"crossref","first-page":"104583","DOI":"10.1016\/j.exphem.2024.104583","article-title":"Mechanistic insights into the developmental origin of pediatric hematologic disorders","volume":"136","author":"Camiolo","year":"2024","journal-title":"Exp Hematol"},{"issue":"4","key":"2026062308475876300_bib61","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/cas.16454","article-title":"A phase I, first in-human study of CBA-1205, an anti-DLK1 monoclonal antibody, in patients with advanced solid tumors","volume":"116","author":"Katsuya","year":"2025","journal-title":"Cancer Sci"},{"issue":"suppl 6","key":"2026062308475876300_bib62","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1158\/1538-7445.AM2024-1896","article-title":"Therapeutic potential of TORL-4-500, an antibody-drug conjugate directed against delta like non-canonical notch ligand 1 (DLK1) [abstract]","volume":"84","author":"McDermott","year":"2024","journal-title":"Cancer Res"},{"issue":"suppl 4","key":"2026062308475876300_bib63","first-page":"TPS672","article-title":"A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumors and carcinomas","volume":"43","author":"Rivero","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4120\/2526586\/blooda_adv-2025-018830-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/12\/4120\/2526586\/blooda_adv-2025-018830-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:57:12Z","timestamp":1782219432000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/12\/4120\/567602\/DLK1-is-a-GATA1s-driven-dependency-and-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018830","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.08.30.608947","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,23]]},"published":{"date-parts":[[2026,6,10]]}}}